192 related articles for article (PubMed ID: 25942648)
1. Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review.
Steele AN; Grimsrud KN; Sen S; Palmieri TL; Greenhalgh DG; Tran NK
J Burn Care Res; 2015; 36(3):e194-211. PubMed ID: 25942648
[TBL] [Abstract][Full Text] [Related]
2. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.
Blanchet B; Jullien V; Vinsonneau C; Tod M
Clin Pharmacokinet; 2008; 47(10):635-54. PubMed ID: 18783295
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.
Ortwine JK; Pogue JM; Faris J
J Burn Care Res; 2015; 36(2):e72-84. PubMed ID: 25167375
[TBL] [Abstract][Full Text] [Related]
4. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury.
Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS
Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics in patients with burns.
Jaehde U; Sörgel F
Clin Pharmacokinet; 1995 Jul; 29(1):15-28. PubMed ID: 7586895
[TBL] [Abstract][Full Text] [Related]
6. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.
Gomez DS; Sanches-Giraud C; Silva CV; Oliveira AM; da Silva JM; Gemperli R; Santos SR
J Antibiot (Tokyo); 2015 Mar; 68(3):143-7. PubMed ID: 25227503
[TBL] [Abstract][Full Text] [Related]
7. Vecuronium pharmacokinetics in patients with major burns.
Vega-Villa KR; Kaneda K; Yamashita S; Woo S; Han TH
Br J Anaesth; 2014 Feb; 112(2):304-10. PubMed ID: 24067332
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients.
Pruskowski KA
Surg Infect (Larchmt); 2021 Feb; 22(1):77-82. PubMed ID: 33164665
[No Abstract] [Full Text] [Related]
9. Protective effect of polydatin against burn-induced lung injury in rats.
Li T; Cai S; Zeng Z; Zhang J; Gao Y; Wang X; Chen Z
Respir Care; 2014 Sep; 59(9):1412-21. PubMed ID: 24825914
[TBL] [Abstract][Full Text] [Related]
10. Individualised vancomycin doses for paediatric burn patients to achieve PK/PD targets.
Gomez DS; Campos EV; de Azevedo RP; Silva JM; Ferreira MC; Sanches-Giraud C; Silva CV; Santos SR
Burns; 2013 May; 39(3):445-50. PubMed ID: 22867735
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
De Paepe P; Belpaire FM; Buylaert WA
Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic relationships for analgesics.
Suri A; Estes KS; Geisslinger G; Derendorf H
Int J Clin Pharmacol Ther; 1997 Aug; 35(8):307-23. PubMed ID: 9266286
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock.
Varghese JM; Roberts JA; Lipman J
Crit Care Clin; 2011 Jan; 27(1):19-34. PubMed ID: 21144984
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic considerations for pediatric patients receiving analgesia in the intensive care unit; targeting postoperative, ECMO and hypothermia patients.
Zeilmaker GA; Pokorna P; Mian P; Wildschut ED; Knibbe CAJ; Krekels EHJ; Allegaert K; Tibboel D
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):417-428. PubMed ID: 29623729
[TBL] [Abstract][Full Text] [Related]
15. New concept and a theoretical consideration of the mechanism-based pharmacokinetics/ pharmacodynamics (PK/PD) modeling for antimicrobial agents.
Sato N; Suzuki H; Hayashi H; Shibasaki S; Sugano T; Maebashi K; Kurosawa T; Shiomi M; Ogata H
Jpn J Antibiot; 2008 Oct; 61(5):314-38. PubMed ID: 19260351
[TBL] [Abstract][Full Text] [Related]
16. PK-PD Compass: bringing infectious diseases pharmacometrics to the patient's bedside.
Bulik CC; Bader JC; Zhang L; Van Wart SA; Rubino CM; Bhavnani SM; Sweeney KL; Ambrose PG
J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):161-177. PubMed ID: 28353185
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.
Zhang L; Beal SL; Sheinerz LB
J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):405-16. PubMed ID: 15000422
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics/Pharmacodynamics models of veterinary antimicrobial agents.
Luo W; Chen D; Wu M; Li Z; Tao Y; Liu Q; Pan Y; Qu W; Yuan Z; Xie S
J Vet Sci; 2019 Sep; 20(5):e40. PubMed ID: 31565887
[TBL] [Abstract][Full Text] [Related]
19. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs.
Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
Int J Antimicrob Agents; 2002 Apr; 19(4):355-8. PubMed ID: 11978507
[TBL] [Abstract][Full Text] [Related]
20. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
Mouton JW; Dudley MN; Cars O; Derendorf H; Drusano GL
J Antimicrob Chemother; 2005 May; 55(5):601-7. PubMed ID: 15772142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
